Deals In Depth: October 2017
Eli Lilly made a big commitment to immuno-oncology with its $1.8 billion deal for CureVac's mRNA vaccines. Amneal and Impax merged, creating the fifth-largest generics company in the US. Billion-dollar aggregates were reached in FOPOs, debt, and late-stage venture pharma financing.
You may also be interested in...
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.